MedPath

ICATIBANT

These highlights do not include all the information needed to use ICATIBANT INJECTION safely and effectively. See full prescribing information for ICATIBANT INJECTION.ICATIBANT injection, for subcutaneous useInitial U.S. Approval: 2011

Approved
Approval ID

39ecd008-37af-4105-84a0-c0cb98b8d0ec

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 29, 2024

Manufacturers
FDA

Apotex Corp.

DUNS: 845263701

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

icatibant acetate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code60505-6214
Application NumberANDA212081
Product Classification
M
Marketing Category
C73584
G
Generic Name
icatibant acetate
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateFebruary 29, 2024
FDA Product Classification

INGREDIENTS (5)

sodium hydroxideInactive
Code: 55X04QC32I
Classification: IACT
icatibant acetateActive
Quantity: 30 mg in 3 mL
Code: 325O8467XK
Classification: ACTIM
acetic acidInactive
Code: Q40Q9N063P
Classification: IACT
sodium chlorideInactive
Code: 451W47IQ8X
Classification: IACT
waterInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ICATIBANT - FDA Drug Approval Details